Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer and prior trastuzumab therapy. Overexpression of HER2 was reported in other canc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Bog |
| Udgivet: |
Wolters Kluwer Medknow Publications,
2016-01-01T00:00:00Z.
|
| Fag: | |
| Online adgang: | Connect to this object online. |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Internet
Connect to this object online.3rd Floor Main Library
| Klassifikationsnummer: |
A1234.567 |
|---|---|
| Kopi 1 | Tilgængelig |